NEWS14 September 2011

Physician research rivals ImpactRx and TargetRx merge

M&A North America

US— ImpactRx has bought TargetRx, a rival in the field of physician survey research. The two firms will merge under the ImpactRx banner.

Gregory Ellis (pictured), who was recently appointed CEO of ImpactRx by its new owners Symphony Technology Group, will lead the merged business.

TargetRx launched in 1999 and works principally with pharmaceutical and biotech firms to help them understand the drivers of product choice and brand adoption among doctors. Its CEO is Craig Scott.

ImpactRx, meanwhile, maintains panels of physicians to monitor the effect that product promotions have on their prescribing behaviour.

Ellis said: “Together, we will provide our clients with an unprecedented level of insight into what physicians do and why they do it.”